Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT01337037 Recruiting - Lung Cancer Clinical Trials

Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)

Start date: April 2011
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to modify the surgical technique of VATS (video-assisted thoracoscopic surgery) lobectomy for early-stage non-small cell lung cancer.

NCT ID: NCT01332240 Recruiting - Clinical trials for Stage III Lung Cancer

External ValidatIon Trial of ASTER Trial

EVITA
Start date: April 2011
Phase: N/A
Study type: Interventional

As the use of endoscopic ultrasonography for mediastinal diagnosis and/or staging is widely spread in Belgium, the investigators aimed to determine the number of mediastinoscopies needed to detect one additional mediastinal lymph node invasion during routine clinical practice in the staging of potentially resectable clinical stage III non-small cell lung cancer.

NCT ID: NCT01312337 Recruiting - Clinical trials for Nonsmall Cell Lung Cancer

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The investigators will examine efficacy and toxicity of gefitinib in Korean patients with EGFR wild tumors diagnosed with direct sequence test.

NCT ID: NCT01305967 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer

Start date: January 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine efficacy of SB injection in Non Small Cell Lung Cancer.

NCT ID: NCT01270399 Recruiting - Clinical trials for The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Start date: January 2011
Phase: Phase 0
Study type: Observational

Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed. Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included). The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.

NCT ID: NCT01258478 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Lung Cancer Rehabilitation Study

LCRS
Start date: December 2010
Phase: N/A
Study type: Interventional

Patients suffering from non small cell lung cancer(NSCLC), depend upon lung removal to increase their chances of survival. But, this type of surgery cannot be advised to patients with significant heart disease, limited lung fuction or reduced physical fitness. Intensive physical training has been shown to increase aerobic fitness in healthy subjects. The purpose of this study is to determine the effect of a short term rehabilitation prior to surgery on the post-operative and physiological outcomes for patients undergoing this type of surgery.

NCT ID: NCT01255059 Recruiting - Clinical trials for Non-small Cell Lung Cancer

GWAS Research of Lung Cancer in Tianjin

Start date: June 2010
Phase: N/A
Study type: Observational

To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

NCT ID: NCT01254591 Recruiting - Breast Cancer Clinical Trials

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Start date: November 2006
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures, such as positron emission tomography/computed tomography (PET/CT) scanning before surgery, may help measure the extent of disease. PURPOSE: This clinical trial is studying PET/CT scanning before surgery in patients with non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, or head and neck cancer.

NCT ID: NCT01249066 Recruiting - Lung Adenocarcinoma Clinical Trials

Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

Start date: September 2010
Phase: N/A
Study type: Observational

AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

NCT ID: NCT01249053 Recruiting - Lung Adenocarcinoma Clinical Trials

Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

Start date: August 2010
Phase: N/A
Study type: Observational

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.